HRES 1154
115th Congress
House
Health
Business investment and capital
Congressional tributes
Drug safety, medical device, and laboratory regulation
Drug therapy
Health care quality
Health promotion and preventive care
Medical research
Research and development
Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.
Introduced: November 16, 2018
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 16, 2018
Referred to the House Committee on Energy and Commerce.
Nov 16, 2018
Introduced in House
Plain-English summary
Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.
Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1
Cosponsors
1